Transplant; Complication, Rejection
10
0
1
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 10 trials
100.0%
+13.5% vs benchmark
10%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (10)
Assessing Benchmarks For Allosure And Allomap Testing in Simultaneous Kidney & Pancreas Transplant Recipients.
Cohort/Ethics Study of Patients With Severe Alcoholic Hepatitis Undergoing Early Liver Transplantation
Cf-DNA Assay During Treatment of Acute Rejection
Liver Transplantation After ex Vivo Liver Perfusion
ALLoreactive T-Cell receptOr RePertoire in kidnEy tranSplantation
Volatile Organic Compounds as Markers of Acute Rejection in Lung Transplant
Mechanistic Evaluation of Treatments for Acute Antibody-Mediated Rejection of the Kidney Transplant
The Endoscopic Assesment of Intestinal Grafts
Blood-Bile Ratio Tacrolimus After Liver Transplantation
Efficacy and Safety of Induction Strategies Combined With Low Tacrolimus Exposure in Kidney Transplant Recipients Receiving Everolimus or Sodium Mycophenolate